Aptose Biosciences APTO

$ 0.28 67.39%

Quarterly report 2024-Q2
added 08-08-2024

Aptose Biosciences Balance Sheet 2011-2024 | APTO

Annual Balance Sheet Aptose Biosciences

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-8.24 M	-35.7 M	-38.5 M	-116 M	-78.3 M	-15.3 M	-10.6 M	-7.93 M	-8.29 M	-17.4 M	-634 K	563 K	-933 K
Long Term Debt	621 K	1 M	115 K	-	-	-	-	-	-	487 K	-	-	-
Long Term Debt Current	394 K	301 K	459 K	539 K	521 K	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	535 K	1.01 M	-	-	-	-	487 K	-	-	-
Total Current Liabilities	15.3 M	12.3 M	8.17 M	6.81 M	5.54 M	2.79 M	1.76 M	-	-	-	-	-	-
Total Liabilities	15.9 M	13.3 M	8.29 M	7.35 M	6.55 M	2.79 M	1.76 M	1.32 M	1.7 M	2.27 M	1.76 M	2.62 M	1.19 M
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-516 M	-464 M	-423 M	-357 M	-302 M	-276 M	-247 M	-187 M	-168 M	-194 M	-194 M	-189 M	-194 M
Total Assets	13 M	51 M	82.5 M	126 M	100 M	16.9 M	12 M	8.64 M	15.3 M	28.5 M	1 M	648 K	2.05 M
Cash and Cash Equivalents	9.25 M	37 M	39.1 M	117 M	79.8 M	15.3 M	10.6 M	-	-	-	-	-	-
Book Value	-2.9 M	37.7 M	74.2 M	119 M	93.9 M	14.1 M	10.2 M	7.32 M	13.6 M	26.2 M	-758 K	-1.97 M	865 K
Total Shareholders Equity	-2.9 M	37.7 M	74.2 M	119 M	93.9 M	14.1 M	10.2 M	7.33 M	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Aptose Biosciences

	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	414 K	520 K	621 K	720 K	817 K	918 K	1 M	1 K	-	10 K	115 K	218 K	321 K	420 K	535 K	535 K	535 K	535 K	1.01 M	1.01 M	1.01 M	1.01 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	13.1 M	12.7 M	15.9 M	13.1 M	12.8 M	13.3 M	13.3 M	10.2 M	-	7.32 M	8.29 M	8.52 M	8.03 M	5.79 M	7.35 M	7.35 M	7.35 M	7.35 M	6.55 M	6.55 M	6.55 M	6.55 M	2.79 M	2.79 M	2.79 M	2.79 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-532 M	-525 M	-516 M	-504 M	-492 M	-478 M	-464 M	-454 M	-	-434 M	-423 M	-398 M	-387 M	-373 M	-357 M	-357 M	-357 M	-357 M	-302 M	-302 M	-302 M	-302 M	-276 M	-276 M	-276 M	-276 M	-247 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	10.9 M	12.8 M	13 M	20.9 M	26.6 M	39.3 M	51 M	57 M	-	72.6 M	82.5 M	97.2 M	106 M	115 M	126 M	126 M	126 M	126 M	100 M	100 M	100 M	100 M	16.9 M	16.9 M	16.9 M	16.9 M	12 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	8.33 M	7.35 M	9.25 M	15.7 M	8.4 M	22.8 M	37 M	28 M	-	37 M	39.1 M	75.1 M	83.3 M	87.1 M	117 M	117 M	117 M	117 M	79.8 M	79.8 M	79.8 M	79.8 M	15.3 M	15.3 M	15.3 M	15.3 M	10.6 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	-2.18 M	137 K	-2.9 M	7.78 M	13.8 M	26 M	37.7 M	46.8 M	-	65.3 M	74.2 M	88.7 M	98.2 M	109 M	119 M	119 M	119 M	119 M	93.9 M	93.9 M	93.9 M	93.9 M	14.1 M	14.1 M	14.1 M	14.1 M	12 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	-2.18 M	137 K	-2.9 M	7.78 M	13.8 M	26 M	37.7 M	46.8 M	55.5 M	65.3 M	74.2 M	88.7 M	98.2 M	109 M	119 M	119 M	119 M	119 M	93.9 M	93.9 M	93.9 M	93.9 M	14.1 M	14.1 M	14.1 M	14.1 M	10.2 M	9.82 M	10.3 M	7.77 M	7.33 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency